Suppr超能文献

[评估基线CCL19树突状细胞浸润以预测肺腺癌患者对免疫治疗的反应]

[Assessment of baseline CCL19 dendritic cell infiltration for predicting responses to immunotherapy in lung adenocarcinoma patients].

作者信息

Zhu M, Wang B, Zhang X, Zhou K, Miao Z, Sun J

机构信息

Clinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.

Cancer Hospital of First Affiliated Hospital, Henan University of Science and Technology,Luoyang 471003, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2024 Aug 20;44(8):1529-1536. doi: 10.12122/j.issn.1673-4254.2024.08.11.

Abstract

OBJECTIVE

To explore the correlation of baseline CCL19 dendritic cell (CCL19 DC) infiltration in lung adenocarcinoma microenvironment with immunotherapy efficacy and CD8 T cell infiltration.

METHODS

We retrospectively analyzed the data of patients with lung adenocarcinoma hospitalized at First Affiliated Hospital of Henan University of Science and Technology from January, 2020 to December, 2023, and collected tissue samples from 96 patients undergoing immunotherapy for assessing CCL19 DC and CD8 T cell infiltration using immunofluorescence assay. We evaluated the predictive value of baseline CCL19 DCs for patient responses to immunotherapy using receiver-operating characteristics (ROC) curves and analyzed the correlations of baseline CCL19 DC expression with immunotherapy efficacy and CD8 T cell and cytotoxic T lymphocyte (CTL) infiltrations. In co-culture systems of lung adenocarcinoma PC9 cells, CD8 T cells and DCs (overexpressing CCL19 with or without anti PD-1 antibody treatment), the expressions of granzyme B, perforin, IFN-, and Ki-67 in T cells were analyzed using flow cytometry.

RESULTS

The patients with partial or complete remission following immunotherapy had a significantly higher baseline CCL19 DC infiltration level in lung adenocarcinoma tissues than those with poor responses. CCL19 DC infiltration had an area under ROC curve of 0.785, a sensitivity of 75.6%, and a specificity of 62.8% for predicting immunotherapy efficacy. The expression of CD8 T cell surface molecules Granzyme B (<0.01), Perforin (<0.01), IFN- (<0.01) and Ki-67 (<0.001) in patients with high expression of CCL19 DC were higher than those in patients with low expression of CCL19 DC. The baseline CCL19 DC infiltration level was positively correlated with immunotherapy efficacy (=0.003), CTL infiltration of (=0.6657, <0.001) and CD8 T cell infiltration (=0.007). In the co-cultured cells, CCL19 overexpression combined with anti-PD1 treatment of the DCs more strongly enhanced cytotoxicity and proliferation of CD8 T lymphocytes than either of the single treatments (<0.01 or 0.001).

CONCLUSION

The baseline CCL19 DC infiltration level in lung adenocarcinoma microenvironment is positively correlated with immunotherapy efficacy and CTL infiltration and can thus predict the response to immunotherapy.

摘要

目的

探讨肺腺癌微环境中基线CCL19树突状细胞(CCL19 DC)浸润与免疫治疗疗效及CD8 T细胞浸润的相关性。

方法

回顾性分析2020年1月至2023年12月在河南科技大学第一附属医院住院的肺腺癌患者的数据,并收集96例接受免疫治疗患者的组织样本,采用免疫荧光法评估CCL19 DC和CD8 T细胞浸润情况。使用受试者工作特征(ROC)曲线评估基线CCL19 DC对患者免疫治疗反应的预测价值,并分析基线CCL19 DC表达与免疫治疗疗效、CD8 T细胞及细胞毒性T淋巴细胞(CTL)浸润的相关性。在肺腺癌PC9细胞、CD8 T细胞和DC(过表达CCL19,有无抗PD-1抗体处理)的共培养体系中,采用流式细胞术分析T细胞中颗粒酶B、穿孔素、IFN-和Ki-67的表达。

结果

免疫治疗后部分或完全缓解的患者,其肺腺癌组织中基线CCL19 DC浸润水平显著高于反应较差的患者。CCL19 DC浸润对免疫治疗疗效的预测,ROC曲线下面积为0.785,灵敏度为75.6%,特异度为62.8%。CCL19 DC高表达患者的CD8 T细胞表面分子颗粒酶B(<0.01)、穿孔素(<0.01)、IFN-(<0.01)和Ki-67(<0.001)的表达高于CCL19 DC低表达患者。基线CCL19 DC浸润水平与免疫治疗疗效(=0.003)、CTL浸润(=0.6657,<0.001)和CD8 T细胞浸润(=0.007)呈正相关。在共培养细胞中,CCL19过表达联合DC的抗PD1处理比单一处理更能强烈增强CD8 T淋巴细胞的细胞毒性和增殖(<0.01或0.001)。

结论

肺腺癌微环境中基线CCL19 DC浸润水平与免疫治疗疗效及CTL浸润呈正相关,因此可预测免疫治疗反应。

相似文献

1
[Assessment of baseline CCL19 dendritic cell infiltration for predicting responses to immunotherapy in lung adenocarcinoma patients].
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Aug 20;44(8):1529-1536. doi: 10.12122/j.issn.1673-4254.2024.08.11.
3
[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):236-244. doi: 10.3779/j.issn.1009-3419.2021.102.15.
4
CCL19 dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.
Med. 2023 Jun 9;4(6):373-393.e8. doi: 10.1016/j.medj.2023.04.008. Epub 2023 May 17.
8
HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma.
J Immunother. 2024 Oct 1;47(8):313-322. doi: 10.1097/CJI.0000000000000535. Epub 2024 Jul 15.
10
Transcription factor RUNX3 promotes CD8 T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment.
J Cell Biochem. 2020 Jun;121(5-6):3208-3220. doi: 10.1002/jcb.29587. Epub 2020 Jan 3.

本文引用的文献

1
CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.
Aging (Albany NY). 2023 Nov 8;15(21):12369-12387. doi: 10.18632/aging.205184.
3
Current treatments for non-small cell lung cancer.
Front Oncol. 2022 Aug 11;12:945102. doi: 10.3389/fonc.2022.945102. eCollection 2022.
4
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
Clin Cancer Res. 2021 Jul 15;27(14):4109-4125. doi: 10.1158/1078-0432.CCR-21-1694. Epub 2021 May 25.
5
Chemokine CXCL14; a double-edged sword in cancer development.
Int Immunopharmacol. 2021 Aug;97:107681. doi: 10.1016/j.intimp.2021.107681. Epub 2021 Apr 28.
7
CXC chemokine ligand 16: a Swiss army knife chemokine in cancer.
Expert Rev Mol Med. 2021 Apr 21;23:e4. doi: 10.1017/erm.2021.7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验